|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Investments: | ||||||||||||||||||||
| Fixed maturities, available for sale, at fair value (net of allowance for credit losses: June 30, 2026 - $41.5 and December 31, 2025 - $36.0; amortized cost: June 30, 2026 - $26,580.2 and December 31, 2025 - $25,776.4) | ||||||||||||||||||||
| Equity securities at fair value | ||||||||||||||||||||
| Mortgage loans (net of allowance for credit losses: June 30, 2026 - $17.0 and December 31, 2025 - $20.9) | ||||||||||||||||||||
| Policy loans | ||||||||||||||||||||
| Trading securities | ||||||||||||||||||||
| Investments held by variable interest entities (net of allowance for credit losses: June 30, 2026 - $1.6 and December 31, 2025 - $0.6; amortized cost: June 30, 2026 - $296.2 and December 31, 2025 - $294.1) | ||||||||||||||||||||
| Other invested assets | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Cash and cash equivalents - unrestricted | ||||||||||||||||||||
| Cash and cash equivalents held by variable interest entities | ||||||||||||||||||||
| Accrued investment income | ||||||||||||||||||||
| Present value of future profits | ||||||||||||||||||||
| Deferred acquisition costs and sales inducements | ||||||||||||||||||||
| Reinsurance receivables (net of allowance for credit losses: June 30, 2026 - $1.0 and December 31, 2025 - $1.0) | ||||||||||||||||||||
| Market risk benefit asset | ||||||||||||||||||||
| Income tax assets, net | ||||||||||||||||||||
| Assets held in separate accounts | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Liabilities for insurance products: | ||||||||||||||||||||
| Policyholder account balances | ||||||||||||||||||||
| Future policy benefits | ||||||||||||||||||||
| Market risk benefit liability | ||||||||||||||||||||
| Liability for life insurance policy claims | ||||||||||||||||||||
| Unearned and advanced premiums | ||||||||||||||||||||
| Liabilities related to separate accounts | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Investment borrowings | ||||||||||||||||||||
| Borrowings related to variable interest entities | ||||||||||||||||||||
| Notes payable – direct corporate obligations | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders' equity: | ||||||||||||||||||||
| Common stock ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: June 30, 2026 – 92,696,990; December 31, 2025 – 94,484,339) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| Total liabilities and shareholders' equity |
Loading...
